Glancy Binkow & Goldberg LLP
announces that it is investigating potential claims on behalf of investors of
Lannett Company, Inc.
(“Lannett” or the “Company”) (NYSE:LCI) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning Lannett’s business and operations.
Please contact us at (310) 201-9150, or at
to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
Lannett develops, manufactures, markets and distributes generic versions of branded pharmaceutical products in the United States. The investigation is related to the Company’s July 16, 2014, announcement that the Company has received interrogatories from the State of Connecticut Office of the Attorney General in connection with an investigation into pricing of digoxin − a widely used treatment for congestive heart failure.
According to the Company, the Attorney General’s investigation seeks to determine “whether anyone engaged in any activities that resulted in (a) fixing, maintaining or controlling prices of digoxin or (b) allocating and dividing customers or territories relating to the sale of digoxin in violation of Connecticut antitrust law.”
If you purchased Lannett shares, if you have information or would like to
about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact
, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888) 773-9224, by e-mail to
, or visit our website at
. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.